UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand starting at 7:00 a.m. ET on September 13, 2021, through the conference portal and UroGen's website. UroGen focuses on developing innovative treatments for specialty cancers and urologic diseases, with its proprietary RTGel™ technology enhancing drug delivery to the urinary tract. Its investigational product, UGN-102, targets low-grade non-muscle invasive bladder cancer.

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C. Wainwright 23^rd Annual Global Investment Conference. The presentation will be available on-demand via the conference portal and through the Investors section of UroGen’s website, www.urogen.com, beginning at 7:00 a.m. Eastern Time on Monday, September 13, 2021. A replay of the webcast will be available on the website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel^TM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005092/en/

INVESTOR CONTACTS:

Lee Roth

lroth@burnsmc.com

212-213-0006

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma present at the H.C. Wainwright Global Investment Conference?

UroGen Pharma will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, starting at 7:00 a.m. Eastern Time.

Where can I watch UroGen Pharma's conference presentation?

The presentation will be available on-demand via the conference portal and on UroGen’s website.

What technology does UroGen Pharma use for drug delivery?

UroGen Pharma utilizes RTGel™, a proprietary sustained release hydrogel technology, designed to improve drug delivery to the urinary tract.

What is UGN-102 developed by UroGen Pharma?

UGN-102 is an investigational treatment for low-grade non-muscle invasive bladder cancer, designed to ablate tumors using non-surgical methods.

What is the focus area of UroGen Pharma?

UroGen Pharma is dedicated to developing novel solutions for specialty cancers and urologic diseases.